Patients Views & Analysis

Views & Analysis

Accenture’s-Keena-Patel-on-optimising-patient-engagement

Q&A: Accenture’s Keena Patel on optimising patient engagemen...

We speak to Keena Patel, a managing director in Accenture’s Life Sciences practice, about how pharmaceutical companies can improve their game in patient engagement.

Views & Analysis

boost-drug-development-in-orphan-diseases

Joined up thinking and innovation will boost drug developmen...

Fresh thinking and greater collaboration at the European level could accelerate the much-needed development of treatments and cures for children with rare diseases.

Views & Analysis

Where next for patient centricity in pharma?

As patient centricity seems to be hitting a slump, Paul Tunnah lays out the key factors companies need to consider to deliver on its promises.

Views & Analysis

Whitepaper-provides-a-blueprint-to-building-a-patient-centric-company

A blueprint for building a patient-centric pharma company

While the industry appears united in its commitment to patient centricity, the practicalities of embedding the ethos into everyday work is still hotly debated.

Views & Analysis

FCS: A life-limiting condition

GP Karishma Patel tells us about the daily challenges of living with the ultra-rare condition Familial Chylomicronaemia Syndrome (FCS), which prevents the body from breaking down fats.

Views & Analysis

eyeforpharma Patient Summit Europe roundup

eyeforpharma's Patient Summit Europe brought together leading patient innovators from industry and patient associations for two days of sharing, learning and a healthy dose

Q&A: Accenture’s Keena Patel on optimising patient engagemen...

Joined up thinking and innovation will boost drug developmen...

Where next for patient centricity in pharma?

A blueprint for building a patient-centric pharma company

FCS: A life-limiting condition

eyeforpharma Patient Summit Europe roundup

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks